Questions discussed in this category
Would you favor 2nd line chemo (with or without trastuzumab) versus immunotherapy?
Is there any safety data to proceed with TKIs/TDM-1 or to proceed as standard with THP?
For patients who remain NED for years, when would you feel it's appropriate to hold therapy?
What would you offer if the patient is not a candidate for cytotoxic therapy?
Patient has progressed through prior lines of endocrine therapy.
Patient had a clinical T2N0 cancer at diagnosis, completed 6 cycles TCHP, and had 0.2mm residual disease with 80% cellularity, negative sentinel node.
2 populations of cells with 95% negative by FISH (ratio 1.07) and 5% positive by FISH (ratio 10)
Does lymph node positivity change your management?
Are there any studies that compare them?
How would your treatment change given pCR rates are reportedly much lower in triple positive patients?
Of note, the patient received cytotoxic plus HER2 directed adjuvant therapy but declined endocrine therapy.
Do you repeat the loading dose of trastuzumab?
Patient completed neoadjuvant therapy with TCH 2 years prior, and has no evidence of disease outside the CNS on PET/CT.
Given the changing landscape of treatment, some patients may have already received capecitabine previously. Would this impact your treatment rec...
Would you obtain baseline PFT on all patients or only selected high risk patients? Would you repeat PFTs regularly or only if clinically symptomatic?&...
Interest in approach for elderly population especially
Would you consider an anthracycline based substitution vs changing to nab-paclitaxel or a combination with platinum agent?
Would you recommend additional cytotoxic chemotherapy and/or switch her anti-Her therapy to T-DM1?
Especially if HER2 negative on pathological specimen
Asymptomatic brain progression despite CNS surgery and SRS x2 over the past 2 years.
NCCN gives category 2b recommendation for either ER+ or ER-, HER2+ tumors, from the Tolaney NEJM 2015 paper with trastuzumab/paclitaxel. However...
N1mic - few isolated malignant cells in 1 axillary lymph node
In cases where patient received 6 cycles of THP and 1 year of HP
Patient received adjuvant chemotherapy and anti-Her2 therapy 3 years ago.
If yes, would you offer tamoxifen or ovarian suppression plus AI?
Received adjuvant HER2 directed therapy 3 years ago.
This patient underwent mastectomy and ALND (10/28 positive lymph nodes). Immediately following axillary LN dissection (and prior to radiation) imaging...
How would this change if the patient had metastatic HR+,HER2- breast cancer and now has symptomatic pancytopenia secondary to BM involvement after TCH...
The APT trial reported excellent DFS, OS and RFI for tumors <=3cm but few were smaller T2s (2-3 cm) and few were >70 years old.
This is a patient with a 1.8cm node negative HER2 positive tumor that is grade 3, high Ki67, and ER positive.
It is included in favorable histologies on NCCN, but no mention of how to treat based off HER2 status.
Patient only had upfront surgery.
Do you utilize it immediately following chemoRT or wait until disease progression?
If yes, would you still recommend dual HER2 directed therapy?
After the TRYPHAENA trial, neoadjuvant therapy with dual HER2 directed therapy has beco...
Does hormone receptor status impact your decision?
Neratinib was studied following adjuvant trastuzumab. Do you extrapolate that data to give neratinib to patients who have received adjuvant T-DM1 inst...
The patient received THP and now is on maintenance HP when she developed CNS disease.
Which patients should receive TDM-1, Trastuzumab+Pertuzumab or Trastuzumab alone?
Clinical T1c patients were included in the KATHERINE trial that often are treated with adjuvant paclitaxel and trastuzumab
Any factors that would impact this decision (how far along adjuvant trastuzumab, disease characteristics, etc)?
Only a small subset (22-24%) of patients in Katherine trial received a non-anthracycline containing regimen.
One such patient progressed through trastuzumab/pertuzumab/letrozole and TDM1 alone. How would you combine ER+ approaches (eg CDK 4/6 inhibitor ...
For example, in a patient > 70 years old?
Will you incorporate the results from KATHERINE into clinical practice now?
The CREATE-X trial did not include HER-2 positive patients but the ER-negative population benefited from capecitabine. Would you consider capecitabine...
Would you do a pertuzumab-based regimen or T-DM1?
In light of the KATHERINE data- does this change your practice?
The NEJM 2015 paper by Tolaney et al only included 1.5% of patients with micrometastases.
Would you do this for ER+ patients?
According to the PERSEPHONE trial presented on ASCO 2018, in HER2+, non-metastatic breast cancer, 6 months Hercep...
Is there any evidence to use trastuzumab and pertuzumab without doxorubicin?
How does it vary for patients with a history of hypertension, diabetes, CHF, and coronary artery disease?
Would you consider using CKD inhibitors upfront in triple positive breast cancer previously treated with chemotherapy, endocrine therapy, and Hercepti...
Would you consider using ckd inhibitors in triple positive breast cancer previously treated with chemotherapy, endocrine therapy, and Herceptin? NCCN ...
The FDA recently approved neratinib based on data from the ExteNET trial; however, benefit appears modest and the risk of toxicity is not low.
How does prior Her2-directed and/or taxane therapy affect your decision?
Do you ever consider de-escalating or stopping therapy in this situation? What is your approach to this conversation?
25166651926193089174918890849018893872397608873171788638779885848432847570937432838065347916779478086887772577387711532275957575747457367040480873797311611272337300734272067033712569017886663588566406460641962566174617659055769575155235575545951205161476844444708444744864067437743714222425138273773359635403245334631443114312528702719221722501922172312641133
Papers discussed in this category
Breast cancer research : BCR, 2009
Cancer cell, 2012-10-16
Cancer cell, 2016-03-14
Cancer discovery, 2016-07
Cancer, 2015-12-15
Lancet (London, England), 2009-12-19
The Lancet. Oncology, 2014-06
The New England journal of medicine, 2012-11-08
J. Clin. Oncol.,
The New England journal of medicine, 2012-01-12
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-10-10
Annals of oncology : official journal of the European Society for Medical Oncology, 2015-01
Annals of oncology : official journal of the European Society for Medical Oncology, 2014-06
Journal of gastrointestinal oncology, 2016-08
The Lancet. Oncology, 2014-10
Lancet, 2010 Aug 19
N Engl J Med, 2020 May 29
J Clin Oncol, 2020 Mar 24
The New England journal of medicine, 2015-02-19
Cochrane Database Syst Rev, 2008 Apr 16
Eur. J. Cancer, 2013 May 22
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-09-01
N Engl J Med, 2015 Jan 8
N. Engl. J. Med.,
N. Engl. J. Med., 2017-07-13
Annals of oncology : official journal of the European Society for Medical Oncology, 2013-09
Lancet Oncol., 2018 Nov 06
Lancet (London, England), 2014-07-12
Lancet Oncol., 2012-01-01
The Lancet. Oncology, 2013-10
The Lancet. Oncology, 2017-06
The New England journal of medicine, 2019-02-14
The Lancet. Oncology, 2016-03
Lancet Oncol., 2017 Feb 24
Eur. J. Cancer, 2017 May 03
N Engl J Med, 2011 Oct 6
Breast cancer research and treatment, 2018-06
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-08-01
The Lancet. Oncology, 2017-12
Breast, 2013 Dec 22
Breast, 2015 Oct 09
Lancet,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-07-20
Curr Treat Options Oncol, 2019 Mar 14
Breast Cancer, 2016 Feb 13
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-01
The Lancet. Oncology, 2018-07
N. Engl. J. Med., 2019 Dec 11
Anticancer Res.,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-07-01
The New England journal of medicine, 2018-07-12
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-04-20
J. Clin. Oncol., 2019 Oct 16
Lancet Oncol., 2020 Mar 12
The Lancet. Oncology, 2017-08
Breast cancer research and treatment, 2014-11
The oncologist, 2013
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-11-10
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-04-01
Breast Cancer Res. Treat., 2017 Mar 21
Clinical cancer research : an official journal of the American Association for Cancer Research, 2009-12-01
Ann. Oncol., 2013-12-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-07-20
J. Clin. Oncol., 2009 Sep 28
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-02-10
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-05-10
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-08-10
Breast cancer research and treatment, 2011-10
J. Clin. Oncol., 2018 May 30
Cancer Treat Rev, 2013 Jun 10
Clin Cancer Res, 2019 Sep 12
J Clin Oncol, 2018 Aug 14